Romosozumab in postmenopausal women with low bone mineral density

New England Journal of Medicine

Volumn 370, Issue 5, 2014, Pages 412-420

  McClung, Michael R ^a   Grauer, Andreas ^b   Boonen, Steven ^c   Bolognese, Michael A ^e   Brown, Jacques P ^f   Diez Perez, Adolfo ^g   Langdahl, Bente L ^h   Reginster, Jean Yves ^d   Zanchetta, Jose R ⁱ   Wasserman, Scott M ^b   Katz, Leonid ^b   Maddox, Judy ^b   Yang, Yu Ching ^b   Libanati, Cesar ^b   Bone, Henry G ^j  

^a OREGON OSTEOPOROSIS CENTER   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e Bethesda Health Research Center   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ Instituto de Investigaciones Metabolicas   (Argentina)

^j Michigan Bone and Mineral Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; ROMOSOZUMAB;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; HIP; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY TUMOR; LUMBAR SPINE; MULTICENTER STUDY; ONCOCYTOMA; OSSIFICATION; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THORAX PAIN; WRIST FRACTURE;

EID: 84893044528     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1305224     Document Type: Article

References (16)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285: 785-95.
2. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19:1842-4. (Pubitemid 41598769)
3. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22:19-28. (Pubitemid 46032593)
4. Krause C, Korchynskyi O, de Rooij K, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010;285:41614-26.
5. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-43. (Pubitemid 46984775)
6. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10:537-43. (Pubitemid 32184286)
7. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005;15: 928-35. (Pubitemid 40994212)
8. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23:860-9. (Pubitemid 351768804)
9. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of post-menopausal osteoporosis. J Bone Miner Res 2009;24:578-88.
10. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25: 948-59.
11. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012;33:747-83.
12. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013;19:179-92.
13. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
15. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis: affected individuals and gene carriers. J Clin Endocrinol Metab 2005;90:6392-5. (Pubitemid 41759290)
16. van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011;26:2804-11.